


**For Sensitivity in  
Prostaglandin  
Measurement . . .  
Contact #1—  
Seragen**



**Seragen's complete  
<sup>125</sup>I-RIA Kits for:**

**6-Keto Pros-  
taglandin F<sub>1α</sub>  
100 Tubes  
Thrombox-  
ane B<sub>2</sub>  
100 Tubes**

**offer you:**

**Convenience—  
Assay & count in  
the same tube**

**Sensitivity—  
Less than 1pg/0.1  
ml sample**

**Simplicity—Less  
chance for error**

**Dependability—  
Fewer checks &  
repeats**

Seragen is the world leader in measuring prostaglandins with the widest range of <sup>3</sup>H-RIA kits, antisera and prostaglandin standards.

For complete technical information or service call toll free **1-800-343-1346**. In Mass. call (617) 265-6004.

Full color wall chart of Prostaglandin Biosynthetic Pathways available free upon request.



**Seragen, Inc.  
54 Clayton Street  
Boston, MA 02122**

## LETTERS

### Malaria Research

It is good to note that *Science* will be reporting on recent developments in parasitology. Gina Kolata's article "The search for a malaria vaccine" (Research News, 9 Nov., p. 679) does not, however, tell the full story of malaria research in recent years.

The seminal work of Cohen, McGregor, and Carrington in 1961 (1) demonstrated protective antibody to human malaria and provided a basis for believing an effective vaccine to malaria might be possible. But a vaccine cannot be made unless one has a source of antigenic material. Yellow fever and flu virus vaccines are grown in chick embryos, and polio vaccines are grown in tissue culture. In 1975, when the World Health Organization embarked on its Programme of Research on Tropical Diseases, there was no way of producing any amount of human malaria parasites. No stage of the parasite could be grown in culture, and there were no suitable experimental animals. Cultivation of the parasites was the first priority. This was achieved in 1976, when a relatively simple method for continuous culture of the erythrocytic stages of *Plasmodium falciparum* was reported (2). This work sparked the revival of hope for a malaria vaccine. For the first time a way was available to produce quantities of human malaria parasites in any reasonably equipped laboratory. This meant that antigens could be purified from such cultures and tested for immunization. At this time there was no way to produce sporozoites in adequate amounts. This was the real reason why a sporozoite vaccine did not seem feasible. Then came the methods for monoclonal antibodies and recombinant DNA, and these have been exploited very effectively by Ruth and Victor Nussenzweig.

The work on a merozoite vaccine discussed in Kolata's article depends on the culture method, yet cultures are not mentioned. Nor does Kolata mention one of the most significant results published so far—the report by Perrin *et al.* (3) showing effective immunization of laboratory-bred squirrel monkeys to *P. falciparum* with very small amounts of a highly purified surface component prepared from cultures of erythrocytic stages. It is important and encouraging that the protein was prepared from one isolate of *P. falciparum*, whereas the challenge infection was derived from an entirely different isolate highly adapted to the squirrel monkey.

The work on a gamete vaccine likewise rests squarely on cultivation of the erythrocytic stages. In these cultures we can produce gametocytes infective to mosquitoes, thus providing a source of sporozoites. The cultures are also being widely used to screen for new drugs and to study the mode of drug action and the remarkable physiological relationships between the parasite and its host erythrocyte.

WILLIAM TRAGER

Department of Parasitology,  
Rockefeller University,  
1230 York Avenue,  
New York 10021-6399

#### References

1. S. Cohen, I. A. McGregor, S. Carrington, *Nature (London)* **192**, 733 (1961).
2. W. Trager and J. B. Jensen, *Science* **193**, 673 (1976).
3. L. H. Perrin *et al.*, *J. Exp. Med.* **160**, 441 (1984).

### Reported Laboratory Frauds in Biomedical Sciences

In recent years, we appear to have been hit by a wave of accounts in journals and newspapers of fraudulent reporting of scientific data. Many factors may have contributed to this, including an increase in the number of persons devoting substantially full time to research; an increase in the competition for available support dollars; an increase in the pressure to publish abundantly; possible changes in the nature of the training process that leads to the Ph.D. degree; and possibly, just possibly, a deterioration in the morality of our scientists. Assignment of weights to each of these and other factors is, at this time, not possible. However, review of reported cases indicates that certain generalities may be noted.

The frauds appear to occur most frequently in our most prestigious research and teaching institutions. A young man enters the laboratory of a very successful investigator, one who has an unusually large bibliography and who has, therefore, secured generous grant support and abundant laboratory space. The young man (there is a paucity of cases in which women are involved in fraud) inspects his new environment to ascertain what it takes to succeed there, and he soon concludes that, since his preceptor, who is obviously successful, has published an unusually large number of papers, this is the route to success. He therefore tries to follow this example and may publish ten or more papers in a year. Those of us experienced in the production of bio-